U.S. markets open in 1 hour 36 minutes

Medical Marijuana, Inc. (MJNA)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0284+0.0009 (+3.27%)
At close: 3:59PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0275
Open0.0280
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0266 - 0.0312
52 Week Range0.0100 - 0.0400
Volume38,104,435
Avg. Volume30,935,064
Market Cap58.336M
Beta (5Y Monthly)0.11
PE Ratio (TTM)14.20
EPS (TTM)0.0020
Earnings DateNov 17, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Medical Marijuana, Inc. Subsidiary Kannaway® Unveils Anticipated New Products in U.S. and Europe at 2021 Focus Virtual Kickoff Event
    GlobeNewswire

    Medical Marijuana, Inc. Subsidiary Kannaway® Unveils Anticipated New Products in U.S. and Europe at 2021 Focus Virtual Kickoff Event

    Medical Marijuana, Inc. Medical Marijuana, Inc. Subsidiary Kannaway® Unveils Anticipated New Products in U.S. and Europe SAN DIEGO, CA, Jan. 25, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its subsidiary Kannaway® has launched several new products in the U.S. and Europe as part of the Company’s 2021 Focus Virtual Kickoff Event. These newly launched products include the Company’s cannabigerol (CBG) tincture in the U.S. and a brand new Green Hemp (cannabidiol) CBD Oil in Europe “Cannabis continues to grow in global acceptance and the future of the industry is going to lie with those who understand the potential benefits of the entire hemp plant in addition to CBD. That’s why we’re looking forward to sharing these new products with consumers in the U.S. and Europe as we extract the nutrients straight from the hemp plant and deliver it to homes around the world,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “We have received a very positive response to our CBG product from the European market and are confident consumers in the U.S. will love it as well.” In December 2020, the Company received a warm welcome into the European CBG market. In the U.S., Kannaway® has officially launched its Pure CBG tincture. Each one-ounce bottle of the tincture infuses 1,000 mg of CBG isolate into multi-chain triglyceride (MCT) oil for increased absorption. Kannaway®'s Green Hemp Oil, now available to consumers in Europe, combines organic hemp seed oil with raw hemp oil to bring the nutrition of broad-spectrum cannabinoids as they are found in a live hemp plant right to your home. Each one-ounce bottle contains 500 mg of CBD and its acidic precursor CBDA. To learn more about these products and/or purchase them, please visit https://kannaway.com/shop.html. About Kannaway® Kannaway® is a network sales and marketing company specializing in the sales and marketing of hemp-based botanical products. Kannaway® currently hosts weekly online sales meetings and conferences across the United States, offering unique insight and opportunity to sales professionals who are desirous of becoming successful leaders in the sale and marketing of hemp-based botanical products. About Medical Marijuana, Inc. We are a company of firsts®. Medical Marijuana, Inc. (MJNA) is a cannabis company with three distinct business units in the non-psychoactive cannabinoid space: a global portfolio of cannabinoid-based nutraceutical brands led by Kannaway® and HempMeds®; a pioneer in sourcing the highest-quality legal non-psychoactive cannabis products derived from industrial hemp; and a cannabinoid-based clinical research and botanical drug development sector led by its pharmaceutical investment companies and partners including AXIM® Biotechnologies, Inc. and Neuropathix, Inc. Medical Marijuana, Inc. was named a top CBD producer by CNBC. Medical Marijuana, Inc. was also the first company to receive historic import permits for CBD products from the governments of Brazil, Mexico, Argentina, and Paraguay and is a leader in the development of international markets. The company’s flagship product Real Scientific Hemp Oil has been used in several successful clinical studies throughout Mexico and Brazil to understand its safety and efficacy. Medical Marijuana, Inc.’s headquarters is in San Diego, California, and additional information is available at OTCMarkets.com or by visiting www.medicalmarijuanainc.com. To see Medical Marijuana, Inc.’s corporate video, click here. Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.’s shop. FORWARD-LOOKING DISCLAIMER This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein. FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. LEGAL DISCLOSURE Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act. CONTACT:Public Relations Contact:Kathryn BrownAccount SupervisorCMW MediaP. 858-264-6600kathryn@cmwmedia.comwww.cmwmedia.comInvestor Relations Contact:P. (858) 283-4016Investors@medicalmarijuanainc.com Attachment Medical Marijuana, Inc.

  • Medical Marijuana, Inc. CEO Honored as 2020 Best Business Leader in the United States by Global Brands Magazine
    GlobeNewswire

    Medical Marijuana, Inc. CEO Honored as 2020 Best Business Leader in the United States by Global Brands Magazine

    MJNA Medical Marijuana, Inc. CEO Honored as 2020 Best Business Leader in the United States by Global Brands Magazine SAN DIEGO, CA, Jan. 19, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its CEO Dr. Stuart Titus has been named the winner of the 2020 Best Business Leader in the United States by Global Brands Magazine. The Global Brand Awards is an annual awards program held by Global Brands Magazine (GBM), headquartered in the UK. Each year, GBM conducts a series of awards for companies that have stood out among industry leaders, demonstrating exceptional service and unique vision. This is the eighth edition of the awards. Dr. Titus is a pioneer of the cannabis industry with more than 10 years of experience within the hemp and cannabidiol (CBD) space. He oversees a robust portfolio of subsidiary and investment companies and through his leadership, Medical Marijuana, Inc. became the first company to develop hemp-based CBD products. Dr. Titus personally helped lead and win legal battles for the importation of CBD into several countries such as Mexico, Brazil, Paraguay, Argentina and many European nations. He has also offered testimony about the safety and wellness benefits of CBD to regulatory agencies in the US, including to the FDA. “While I am certainly honored to receive this award, I want to thank my team of extremely hard-working executives who have helped me take the company to where it is today,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “When I became involved with the company, I could have never imagined the growth and prosperity that we have achieved over the past several years. It has been a pleasure to see Medical Marijuana, Inc. become a leader in cannabis and CBD and I look forward to witnessing the entire industry prosper in the years to come.” To view the list of 2020 Global Brands Magazine award winners, visit https://www.globalbrandsmagazine.com/award-winners-2020/ and search under “Leadership Awards.” About Medical Marijuana, Inc. We are a company of firsts®. Medical Marijuana, Inc. (MJNA) is a cannabis company with three distinct business units in the non-psychoactive cannabinoid space: a global portfolio of cannabinoid-based nutraceutical brands led by Kannaway® and HempMeds®; a pioneer in sourcing the highest-quality legal non-psychoactive cannabis products derived from industrial hemp; and a cannabinoid-based clinical research and botanical drug development sector led by its pharmaceutical investment companies and partners including AXIM® Biotechnologies, Inc. and Neuropathix, Inc. Medical Marijuana, Inc. was named a top CBD producer by CNBC. Medical Marijuana, Inc. was also the first company to receive historic import permits for CBD products from the governments of Brazil, Mexico, Argentina, and Paraguay and is a leader in the development of international markets. The company’s flagship product Real Scientific Hemp Oil has been used in several successful clinical studies throughout Mexico and Brazil to understand its safety and efficacy. Medical Marijuana, Inc.’s headquarters is in San Diego, California, and additional information is available at OTCMarkets.com or by visiting www.medicalmarijuanainc.com. To see Medical Marijuana, Inc.’s corporate video, click here. Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.’s shop. FORWARD-LOOKING DISCLAIMER This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein. FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. LEGAL DISCLOSURE Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act. CONTACT: Public Relations Contact: Kathryn Brown Account Supervisor CMW Media P. 858-264-6600 kathryn@cmwmedia.com www.cmwmedia.com Investor Relations Contact: P. (858) 283-4016 Investors@medicalmarijuanainc.com Attachment MJNA

  • Medical Marijuana, Inc. Subsidiary HempMeds® Broadens Offerings to Include CBN and CBG as Part of Company’s Updated Brand Strategy
    GlobeNewswire

    Medical Marijuana, Inc. Subsidiary HempMeds® Broadens Offerings to Include CBN and CBG as Part of Company’s Updated Brand Strategy

    MJNA Medical Marijuana, Inc. Subsidiary HempMeds® Broadens Offerings to Include CBN and CBGSAN DIEGO, CA, Jan. 05, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire \-- Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its subsidiary HempMeds® has launched its first-ever products containing cannabigerol (CBG) and cannabinol (CBN) as part of the Company’s recently updated brand strategy. “When we founded HempMeds a decade ago, we were helping to create the entire CBD category. Since then, CBD has become the booming industry that we expected and acceptance for cannabinoids has come an incredibly long way in the last few years,” said HempMeds® Co-Founder Michelle Sides. “While our flagship RSHO products remain popular, we recognized it was time to expand alongside the industry and broaden our offerings as part of the company’s exciting new direction. We are confident that consumers will be excited about our new CBG and CBN products.”Each 12-ounce bottle of HempMeds®’ RSHO® Calm Support is formulated to promote overall relaxation with 300 mg of CBN, 2,000 mg of CBD and 300 mg of Piperine, naturally derived from black pepper, to increase bioavailability. For those looking for an additional boost of focus, each 12-ounce bottle of RSHO® Focus Support offers 1,500 mg of CBD, 1,500 mg of CBG and 300 mg of Piperine. “It is amazing to think that there are over 100 lesser-known minor cannabinoids in the cannabis plant, each with its own potential benefits. With minor cannabinoids like CBG and CBN growing in popularity, they will likely take over more and more of the expected $47.2 billion global cannabis market. We look forward to continuing to expand and evolve our offerings in response to consumer demand, starting with these new products,” said HempMeds® CEO Raul Elizalde.To learn more about these products and/or purchase them, please visit https://hempmedspx.com/shop/.About HempMeds®Founded in 2012, HempMeds® was the first company to bring hemp-based cannabidiol (CBD) oil products to market in the U.S. As a subsidiary of Medical Marijuana, Inc., HempMeds is the exclusive distributor for premium brands including Real Scientific Hemp Oil™ and Dixie Botanicals®, and operates in all 50 states and 40 countries. HempMeds® is the only company to have its CBD products listed in the Prescribers’ Digital Reference (PDR), the only company invited to speak to the World Health Organization and FDA on the benefits of CBD, and one of the first to be certified by the U.S. Hemp Authority. To learn more, please visit www.hempmedspx.com.About Medical Marijuana, Inc.We are a company of firsts®. Medical Marijuana, Inc. (MJNA) is a cannabis company with three distinct business units in the non-psychoactive cannabinoid space: a global portfolio of cannabinoid-based nutraceutical brands led by Kannaway® and HempMeds®; a pioneer in sourcing the highest-quality legal non-psychoactive cannabis products derived from industrial hemp; and a cannabinoid-based clinical research and botanical drug development sector led by its pharmaceutical investment companies and partners including AXIM® Biotechnologies, Inc. and Neuropathix, Inc. Medical Marijuana, Inc. was named a top CBD producer by CNBC. Medical Marijuana, Inc. was also the first company to receive historic import permits for CBD products from the governments of Brazil, Mexico, Argentina, and Paraguay and is a leader in the development of international markets. The company’s flagship product Real Scientific Hemp Oil has been used in several successful clinical studies throughout Mexico and Brazil to understand its safety and efficacy. Medical Marijuana, Inc.’s headquarters is in San Diego, California, and additional information is available at OTCMarkets.com or by visiting www.medicalmarijuanainc.com. To see Medical Marijuana, Inc.’s corporate video, click here.Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.’s shop.FORWARD-LOOKING DISCLAIMERThis press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSUREThese statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.LEGAL DISCLOSUREMedical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act.CONTACT:Public Relations Contact: Kathryn Brown Account Supervisor CMW Media P. 858-264-6600 kathryn@cmwmedia.com www.cmwmedia.comInvestor Relations Contact: P. (858) 283-4016 Investors@medicalmarijuanainc.comAttachment * MJNA